SeaStar Medical (ICU) Projected to Announce Quarterly Earnings on Thursday

SeaStar Medical (NASDAQ:ICU) is expected to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.95) per share and revenue of $0.50 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

SeaStar Medical (NASDAQ:ICU) last issued its earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.06. SeaStar Medical had a negative net margin of 795.51% and a negative return on equity of 162.75%. The company had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.49 million. On average, analysts expect SeaStar Medical to post ($3.66) EPS for the current fiscal year and ($2.09) EPS for the next fiscal year.

SeaStar Medical Stock Up 2.0%

SeaStar Medical stock opened at $2.04 on Thursday. The company’s fifty day simple moving average is $3.13 and its 200-day simple moving average is $3.30. SeaStar Medical has a 12 month low of $1.90 and a 12 month high of $5.40. The stock has a market cap of $10.85 million, a P/E ratio of -0.52 and a beta of -1.07.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wall Street Zen upgraded SeaStar Medical from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.00.

About SeaStar Medical

SeaStar Medical Holding Corporation (NASDAQ: ICU) is a medical technology company developing therapies designed to address hyperinflammation, an excessive immune response that can contribute to organ damage in critically ill patients. The company’s platform is intended to selectively target and modulate pro-inflammatory immune cells while preserving the body’s broader immune function.

Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-purification device used alongside continuous kidney replacement therapy.